image credit: Adobe Stock

Clinical trial begins using CAR T cells to potentially cure HIV

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy. The novel study uses immunotherapy. It involves taking a patient’s own white blood cells, called T-cells, and modifying them so they can identify and target HIV cells to control the virus without medication.

The first participant was dosed with anti-HIV duoCAR T cells at UC Davis Medical Center in mid-August. The trial is the first-in-human clinical study investigating the duoCAR T-cell therapy for the treatment of HIV.

Read More on World Pharma News